Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3)

The purpose of this grant is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Funding: UG3 $500,000 per year; UH3 no fixed limit 

Duration: UG3 2 years; UH3 3 years

Research Authority due date: 10 days prior to submission 

LOI (encouraged) due dates: 26.2.24, 17.6.24, 19.10.24, 16.2.25, 17.6.25, 19.10.25, 26.2.26, 17.6.26, 19.10.26

Full proposal due dates: 26.3.24, 17.7.24, 19.11.24, 16.3.25, 17.7.25, 19.11.25, 26.3.26, 17.7.26, 19.11.26